2025 Volume 32 Issue 5 Pages 96-105
Peripheral neuropathic pain (PNP) other than diabetic peripheral neuropathic pain (DPNP)/postherpetic neuralgia (PHN) was not the target population in clinical trials of mirogabalin (Tarlige®). To assess the effectiveness of mirogabalin for other types of PNP, this multicenter, prospective, observational study evaluated the effectiveness of mirogabalin in patients with DPNP/PHN (n＝529) and in those with other types of PNP (n＝1,029) in real-world clinical settings. The rate of patients with ≥50％ reduction in pain visual analog scale (VAS) scores was not significantly different between the groups (45.6％ in the DPNP/PHN group and 48.7％ in the other PNP group; median odds ratio [95％ credible interval]: 1.134 [0.919, 1.401]). The overall incidence of adverse drug reactions (ADRs) was 9.08％ (DPNP/PHN 8.63％，other PNP 9.29％). The most common ADRs were dizziness and somnolence, which are expected events with mirogabalin. Given these results, mirogabalin seems effective for other types of PNP. And there were no new safety concerns with mirogabalin in this study.
